How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

28,354 results for

Topical Corticosteroid

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Antenatal Corticosteroid Therapy for Improving Neonatal Outcomes

and adrenal suppression. Intended Users Maternity care providers including midwives, family physicians, and obstetricians. Target Population Pregnant women. Evidence Medline, PubMed, Embase, and the Cochrane Library were searched from inception to September 2017. Medical Subject Heading (MeSH) terms and key words related to pregnancy, prematurity, corticosteroids, and perinatal and neonatal mortality and morbidity were used. Statements from professional organizations including that of the National (...) Institutes of Health, the American College of Obstetricians and Gynecologists, the Society for Maternal Fetal Medicine, the Royal College of Obstetricians and Gynaecologists, and the Canadian Pediatric Society were reviewed for additional references. Randomized controlled trials conducted in pregnant women evaluating antenatal corticosteroid therapy and previous systematic reviews on the topic were eligible. Evidence from systematic reviews of non-experimental (cohort) studies was also eligible

2018 Society of Obstetricians and Gynaecologists of Canada

22. Corticosteroids

the Cochrane Central Register of Controlled Trials (CENTRAL) which contains the Cochrane ARI Group's Specialised Register, MEDLINE (Ovid), Embase (Elsevier), CINAHL (EBSCO), Web of Science (Thomson Reuters), and LILACS (BIREME) for published studies 2018 8. Corticosteroids - inhaled Corticosteroids - inhaled - NICE CKS Clinical Knowledge Summaries Share Corticosteroids - inhaled - Summary Corticosteroids are synthetic analogues of hormones produced by the adrenal cortex. Inhaled corticosteroids (...) of one day earlier. Reduced need for artificial breathing support was the main benefit for people with non-severe pneumonia. The review showed that using corticosteroids increased levels of blood sugar. This and other potential adverse events were not well 2018 12. Corticosteroids - oral Corticosteroids - oral - NICE CKS Clinical Knowledge Summaries Share Corticosteroids - oral - Summary Corticosteroids are synthetic analogues of hormones produced by the adrenal cortex. Corticosteroids are either

2018 Trip Latest and Greatest

23. Assessment of topical corticosteroid ointment on postcesarean scars prevention: A prospective clinical trial. Full Text available with Trip Pro

Assessment of topical corticosteroid ointment on postcesarean scars prevention: A prospective clinical trial. To evaluate the effectiveness of corticosteroid ointment in hypertrophic scars prevention following Cesarean section.This study was conducted between June 2017-May 2018 in Acıbadem Kozyatagı Hospital. Sixty-one patients (31 treatment and 30 control patients) took part in the current study which evaluated wound outcomes and patient satisfaction. All patients' wound characteristics were (...) assessed via the modified Vancouver Scar Scale (MVSS) score (height, pigmentation, vascularity, and pliability) at baseline (post-op 10th day), three months and six months. The treatment group received corticosteroid cream every other day for three months. Comparative evaluations and time-bound changes were evaluated in both groups.The mean age of the subjects was 31.28 ± 3.95 years. While the height and vascularity subsection scores of corticosteroid recipients were significantly reduced compared

2019 Pakistan Journal Of Medical Sciences Controlled trial quality: uncertain

24. A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Oral Administration of a Heat-Treated Lactobacillus paracasei  Supplement in Infants with Atopic Dermatitis Receiving Topical Corticosteroid Therapy. (Abstract)

in lesional and unaffected skin and CCL17 levels. There were no differences between the treatment groups. Total IgE increased over the treatment period in both groups, with significantly higher increase in the heat-treated probiotic group (p = 0.038). There was no evidence of a corticoid "sparing effect" by the probiotic.In this design, the probiotic L. paracasei was not beneficial as a complementary approach to topical corticosteroids in infants with AD. However, slight beneficial effects may have been (...) A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Oral Administration of a Heat-Treated Lactobacillus paracasei  Supplement in Infants with Atopic Dermatitis Receiving Topical Corticosteroid Therapy. Atopic dermatitis (AD) is a common disease in infancy, for which topical steroids are the first-line therapy but have side effects. Innovative approaches are needed to reduce the burden of AD and corticosteroid usage in infants.The once-daily consumption of heat-treated probiotic

2019 Skin pharmacology and physiology Controlled trial quality: predicted high

25. Topical corticosteroid irrigations in chronic rhinosinusitis. Full Text available with Trip Pro

-pressure devices with adequate dosing. Although there is some systemic absorption, multiple studies have demonstrated that long-term, daily use of topical corticosteroids does not increase intraocular pressure, suppress the hypothalamic-pituitary-adrenal axis, or increase the risk of subcapsular cataracts. Therefore, topical corticosteroid irrigations should be considered a part of first-line medical treatment in postsurgical CRS patients.© 2019 ARS-AAOA, LLC. (...) Topical corticosteroid irrigations in chronic rhinosinusitis. Chronic rhinosinusitis (CRS) has previously been thought to occur secondary to infectious or obstructive etiologies. However, in recent years, primary CRS has been more discretely defined as diffuse airway inflammation, similar to asthma. Adequate medical and surgical therapy are needed to control the inflammation. Our purpose in this study was to evaluate the efficacy and safety of topical corticosteroid treatment.A focused

2019 International forum of allergy & rhinology

26. Treatment responses in patients with vitiligo to very potent topical corticosteroids combined with vitaminotherapy in Madagascar. (Abstract)

Treatment responses in patients with vitiligo to very potent topical corticosteroids combined with vitaminotherapy in Madagascar. Vitiligo is a refractory disease in which treatment modalities are not yet established. We aim to assess results obtained 10 years after the initiation of a therapeutic protocol which combines very potent topical corticosteroids (TCS), vitaminotherapy (B12 and C), and suppression of microtraumas in the management of nonsegmental vitiligo in Madagascar.It

2019 International Journal of Dermatology

27. Topical Corticosteroid Phobia Among Healthcare Professionals Using the TOPICOP Score. Full Text available with Trip Pro

Topical Corticosteroid Phobia Among Healthcare Professionals Using the TOPICOP Score. Corticophobia is a major problem in adherence to therapy. This study examined corticophobia among healthcare professionals using the Topical Corticosteroid Phobia (TOPICOP) questionnaire. The TOPICOP questionnaire was adapted for use with professionals (TOPICOP-P). Four groups of professionals: pharmacists, paediatricians, general practitioners and dermatologists were observed. The mean global TOPICOP score (...) knowledge of topical corticosteroids. In order to improve patient compliance, re-education of healthcare providers is suggested.

2019 Acta Dermato-Venereologica

28. Different potencies of topical corticosteroids for a better treatment strategy in children with atopic dermatitis (the Rotterdam Eczema study): protocol for an observational cohort study with an embedded randomised open-label controlled trial. Full Text available with Trip Pro

Different potencies of topical corticosteroids for a better treatment strategy in children with atopic dermatitis (the Rotterdam Eczema study): protocol for an observational cohort study with an embedded randomised open-label controlled trial. Topical corticosteroids (TCS) of different potencies are the main treatment to control atopic dermatitis (AD). The Dutch guideline on AD for general practitioners (GPs) recommends a stepwise approach in which treatment steps are tailored to the severity

2019 BMJ open Controlled trial quality: predicted high

29. Comparison of the effect of photodynamic therapy and topical corticosteroid on oral lichen planus lesions. (Abstract)

Comparison of the effect of photodynamic therapy and topical corticosteroid on oral lichen planus lesions. In this study, the effect of photodynamic therapy with topical corticosteroid in oral lichen planus patients was compared.In this randomized, double-blind clinical trial, eight patients with bilateral oral OLP lesions were recruited. Toluidine blue was applied on the lesions of both sides; a 660-nm diode laser InGaAlP was irradiated for 10 min (power: 25 mW, fluence: 19.23 J/cm2 , probe

2019 Oral diseases Controlled trial quality: uncertain

30. Topical corticosteroids for treatment-resistant atopic dermatitis. (Abstract)

Topical corticosteroids for treatment-resistant atopic dermatitis. Although topical corticosteroids are the mainstay of treatment of atopic dermatitis (AD), these medications may lose efficacy over time, a phenomenon known as tachyphylaxis. However, the underlying mechanism for tachyphylaxis may be due to lack of treatment adherence rather than loss of efficacy of topical corticosteroids. In this study, we aimed to determine if AD patients who were previously unsuccessfully treated with topical (...) corticosteroids would respond to desoximetasone spray 0.25% under conditions designed to promote good adherence over a 7-day period. At baseline, patients were randomized to receive either twice-daily telephone calls to discuss treatment adherence (intervention group) or no telephone calls (control group) during the study period. The patients improved rapidly. In most patients, treatment-resistant AD is most likely due to poor adherence to treatment rather than loss of drug responsiveness.

2019 Cutis Controlled trial quality: uncertain

31. Topical Corticosteroid Pretreatment Mitigates Cellular Damage After Caustic Injury to the Nasal Upper Airway Epithelium. (Abstract)

Topical Corticosteroid Pretreatment Mitigates Cellular Damage After Caustic Injury to the Nasal Upper Airway Epithelium. Topical corticosteroids are currently employed to reduce established airway inflammation; their prophylactic use might help limit cellular damage against harmful stimuli.To determine the effects of a prophylactic topical application of budesonide (BD) on an in vivo nasal epithelium injury model induced by trichloroacetic acid (TCA).C57Bl/6 mice were exposed to intranasal TCA (...) topical application. Three groups received topical intranasal BD, saline solution, or no intervention prior to a single topical exposure to TCA. Controls were not exposed to TCA. Whole nasal cavity coronal sections were analyzed at 1, 3, and 6 days postinjury at tissue and cellular levels using histopathological analysis, immunofluorescent staining, and fresh tissue RNA microarray analysis.Prophylactic topical corticosteroid exposure protected the nasal epithelium from acute damage, maintaining

2019 American journal of rhinology & allergy

32. Correction to: Efficacy and Tolerability of a Medical Device Repairing Emollient Cream Associated with a Topical Corticosteroid in Adults with Atopic Dermatitis: An Open-label, Intra-individual Randomized Controlled Study. Full Text available with Trip Pro

Correction to: Efficacy and Tolerability of a Medical Device Repairing Emollient Cream Associated with a Topical Corticosteroid in Adults with Atopic Dermatitis: An Open-label, Intra-individual Randomized Controlled Study. The original article can be found online.

2019 Dermatology and therapy Controlled trial quality: uncertain

33. Assessment of Topical Corticosteroid Prescribing, Counseling, and Communication Among Dermatologists and Pharmacists. (Abstract)

Assessment of Topical Corticosteroid Prescribing, Counseling, and Communication Among Dermatologists and Pharmacists. Topical corticosteroids (TCs) are common treatments for many dermatologic conditions. Anecdotal experience and literature suggest that dermatologists and pharmacists differ in their beliefs about TCs and approach to TC counseling, creating the opportunity for patient confusion.To examine interprofessional practice gaps between dermatologists and pharmacists with regard to how

2019 JAMA dermatology (Chicago, Ill.)

34. Systemic allergic dermatitis after patch testing with dibucaine and topical corticosteroids. (Abstract)

Systemic allergic dermatitis after patch testing with dibucaine and topical corticosteroids. Systemic allergic dermatitis arises if an individual sensitised via the skin is exposed to the same allergen or a cross reacting allergen by a different route1 . It is rarely elicited by cutaneous contact with an allergen2 , although transepidermal rechallenge has been reported3 . We report a case of systemic allergic dermatitis caused by patch testing. This article is protected by copyright. All rights

2019 Contact Dermatitis

35. Association Between Topical Corticosteroid Use and Type 2 Diabetes in Two European Population-Based Adult Cohorts. Full Text available with Trip Pro

Association Between Topical Corticosteroid Use and Type 2 Diabetes in Two European Population-Based Adult Cohorts. Topical corticosteroids (CSs) are commonly used to treat inflammatory skin conditions including eczema and psoriasis. Although topical CS package inserts describe hyperglycemia and glycosuria as adverse drug reactions, it is unclear whether topical CS use in real life is also associated with an increased risk of type 2 diabetes (T2D).Two matched case-control studies and one cohort (...) study were conducted using routinely collected health care data from Denmark and the U.K. A total of 115,218 and 54,944 adults were identified as case subjects with new-onset T2D in the Danish and U.K. case-control study, respectively. For the Danish cohort study, 2,689,473 adults were included. The main exposure was topical CSs, and the outcome was incident T2D.Topical CS was significantly associated with T2D in the Danish (adjusted odds ratio [OR] 1.35 [95% CI 1.33-1.38]) and U.K. (adjusted

2019 Diabetes Care

36. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. (Abstract)

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Dupilumab (an anti-interleukin-4-receptor-α monoclonal antibody) blocks signalling of interleukin 4 and interleukin 13, type 2/Th2 cytokines implicated in numerous allergic diseases ranging from asthma to atopic dermatitis. Previous 16-week monotherapy studies showed that dupilumab (...) substantially improved signs and symptoms of moderate-to-severe atopic dermatitis with acceptable safety, validating the crucial role of interleukin 4 and interleukin 13 in atopic dermatitis pathogenesis. We aimed to evaluate the long-term efficacy and safety of dupilumab with medium-potency topical corticosteroids versus placebo with topical corticosteroids in adults with moderate-to-severe atopic dermatitis.In this 1-year, randomised, double-blinded, placebo-controlled, phase 3 study (LIBERTY AD CHRONOS

2017 Lancet Controlled trial quality: predicted high

37. Innovations in topical ocular corticosteroid therapy for the management of postoperative ocular inflammation and pain. (Abstract)

Innovations in topical ocular corticosteroid therapy for the management of postoperative ocular inflammation and pain. Topical ophthalmic corticosteroids are of clinical benefit in the management of pain and inflammation after ocular surgery; however, their use can be associated with class-associated adverse events (AEs) and limited bioavailability. Selection of an appropriate topical corticosteroid depends on drug-specific variables such as AE profile, efficacy, potency, dosing, patient (...) etabonate (LE) is a carbon-20 ester corticosteroid developed through retrometabolic drug design with potent anti-inflammatory effects and a reduced propensity for eliciting corticosteroid class AEs. This drug has been formulated for topical ophthalmic use after surgery as 0.5% and 1% suspensions, a 0.5% ointment, and a 0.5% gel. Preclinical and clinical data for a new 0.38% LE gel will be reviewed demonstrating that reducing the drug particle size to the nanometer range in diameter provides effective

2019 American Journal Of Managed Care

38. Corticosteroids Provide Better Postoperative Endodontic Pain Relief Compared to Placebo (CAT#3350)

Corticosteroids Provide Better Postoperative Endodontic Pain Relief Compared to Placebo (CAT#3350) UTCAT3350, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Corticosteroids Provide Better Postoperative Endodontic Pain Relief Compared to Placebo Clinical Question In patients receiving non-surgical endodontic therapy, do corticosteroids provide better postoperative endodontic pain relief compared to placebo? Clinical (...) and dosages of corticosteroids produced different levels of analgesic efficacy. The three main types of corticosteroids studied in this article were prednisolone, dexamethasone, and betamethasone. At 6 hours, prednisolone had a more significant effect on pain relief than the other two drugs due to faster onset. It is speculated that this was because prednisolone has a shorter half-life and diffuses across the cell membrane at a faster rate to affect gene transcription. Applicability This topic

2018 UTHSCSA Dental School CAT Library

39. Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part II) Full Text available with Trip Pro

at Annual Meeting, the European Society of Intensive Care Medicine (EISCM) (co-chair of Corticosteroid Guideline in collaboration with SCCM), and the Korean Society of Critical Care Medicine (co-director and speaker at Multiprofessional Critical Care Board Review Course). He has spoken on the topic of corticosteroid use in critical illness and specifically in sepsis at the International Symposium in Critical and Emergency Medicine in March 2017. Dr. Annane has been involved with research relating (...) Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part II) Guidelines for the Diagnosis and Management of Critical Illn... : Critical Care Medicine You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. Login No user account? Lippincott Journals Subscribers , use your username or email along with your password to log in. Remember me

2018 Society of Critical Care Medicine

40. Intermittent Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists for Asthma

Appendix B. List of Excluded Studies Appendix C. Study Characteristics Appendix D. Risk of Bias Assessment Appendix E. Strength of Evidence Assessments Appendix F. Forest Plots ES-1 Evidence Summary Objectives and Rationale for the Review This report summarizes a systematic review of intermittent inhaled corticosteroids and long- acting muscarinic antagonists for asthma, and identifies needs for future research. This was one of the six high priority topics within asthma identified by a National Heart (...) Intermittent Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists for Asthma Comparative Effectiveness Review Number 194 Intermittent Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists for Asthma e Comparative Effectiveness Review Number 194 Intermittent Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists for Asthma Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857

2018 Effective Health Care Program (AHRQ)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>